

***TERF2* GENE EXPRESSION IN CHILDHOOD  
ACUTE LYMPHOBLASTIC LEUKAEMIA**

**LELAMEKALA VENGIDASAN**

**FACULTY OF SCIENCE  
UNIVERSITY OF MALAYA  
KUALA LUMPUR**

**2011**

***TERF2* GENE EXPRESSION IN CHILDHOOD ACUTE  
LYMPHOBLASTIC LEUKAEMIA**

**LELAMEKALA VENGIDASAN**

**DISSERTATION SUBMITTED IN FULFILLMENT OF  
THE REQUIREMENT FOR THE DEGREE OF  
MASTER OF BIOTECHNOLOGY**

**FACULTY OF SCIENCE  
UNIVERSITY OF MALAYA  
KUALA LUMPUR**

**2011**

## ABSTRACT

Advances in the understanding of cell biology in childhood acute lymphoblastic leukemia (cALL) have led to sophisticated risk-stratification based therapeutic interventions targeting individual patients. Despite these advances, approximately 10-20% of children with ALL still relapse. Thus, identification of new prognostic indicators will allow for better targeted treatment. *TERF2*, one of the main components of the shelterin complex (telosome), has been found to be over-expressed in a variety of epithelial malignancies, including lung, skin and breast cancer. This study aims to investigate the level of expression of *TERF2* in pediatric ALL and in different cALL patient subgroups and its potential as a prognostic marker in such patients.

Diagnostic bone marrow samples were obtained from 72 paediatric patients treated at the University Malaya Medical Centre (UMMC) under the Malaysia-Singapore ALL 2003 study protocol. Expression of *TERF2* was measured via real time quantitative PCR using cDNA synthesized from the samples described above. Results were standardized using *B2M* transcripts as the internal control and HL60 as the calibrator. Relative quantification of gene expression was calculated by using the delta delta Ct method.

Formatted: Left: 2.54 cm, Right: 2.54 cm, Top: 2.54 cm, Bottom: 2.54 cm, Width: 21.59 cm, Height: 27.94 cm

*TERF2* was significantly upregulated in leukemia samples compared to control samples obtained from bone marrow cells and peripheral blood of 'normal' patients and those with non-lymphoblastic malignancies ( $p < 0.05$ ). The range of expression varied amongst the cALL patients. Thus a sequential *TERF2* analysis was performed according to the different cALL subgroups. Over expression of *TERF2* was observed in the *TEL-AML1* subgroup - associated with a good response to chemotherapy- whilst *TERF2* was underexpressed in the *BCR-ABL* subgroup which is associated with a poorer response to treatment.

Our study suggests that overexpression of *TERF2* provides a protective advantage to the chromosomes which ironically, is to the detriment of blast survival. Indeed, the cALL subgroup TEL-AML which overexpresses *TERF2* is associated with a good prognosis whilst the reverse is true for patients with *BCR-ABL1* positive disease. It protects the telomere and subsequently promotes chromosomal stability, thus allowing the cell to undergo normal cell death with viable *ATM* and *p53* signaling pathways. We hypothesize that the ability of the blasts to maintain normal cell cycle and undergo apoptosis allows the different chemotherapy agents which act at various stages of the cell death pathway to be effective thus minimizing the rate of relapse. We conclude that over-expression of *TERF2* results in better treatment outcome in cALL patients. Larger sample size and protein level studies are needed to validate the results of this finding.

## ABSTRAK

Kemajuan dalam pemahaman biologi sel dalam leukemia limfoblastik akut (LLA) telah melahirkan rawatan canggih berdasarkan stratifikasi risiko dan penargetan individu. Walaubagaimanapun, sekitar 10-20% kanak-kanak dengan LLA tidak sembuh sepenuhnya, malah mendapat penyakit ini semula. Oleh yang demikian, penemuan penanda prognostik yang baru akan membantu rawatan ini supaya. *TERF2*, adalah salah satu komponen utama dari kompleks shelterin (telosome) di mana tahap ekspresi dijumpai tinggi dalam pelbagai penyakit berkaitan epitel, termasuk paru-paru, kulit dan kanser payudara. Penyelidikan ini dijalankan dengan tujuan untuk mengetahui tahap ekspresi *TERF2* dalam sub-kumpulan pesakit LLA dan potensinya sebagai penanda prognostik bagi pesakit tersebut.

Sampel sumsum tulang diagnostik diperolehi daripada 72 pesakit kanak-kanak yang dirawat di Pusat Perubatan Universiti Malaya (PPUM) di bawah Protokol Penyelidikan LLA Malaysia-Singapura 2003. Ekspresi *TERF2* ditentukan melalui 'real time PCR' (dipendekan daripada istilah Bahasa Inggeris – polymerase chain reaction) dengan menggunakan komplemen deoksiribonukleat acid (cDNA) (dipendekan daripada istilah Bahasa Inggeris – complement deoxyribonucleic acid) daripada sampel yang dinyatakan di atas. Keputusan telah diselaraskan dengan menggunakan transkrip *β2M* sebagai kawalan dalaman dan HL60 sebagai kalibrator. Kuantifikasi relatif ekspresi gen ditentukan dengan menggunakan kaedah delta delta  $C_T$ .

Ekspresi gen *TERF2* adalah tinggi dalam sampel leukemia berbanding dengan sampel kawalan yang diperolehi daripada sel sumsum tulang dan darah periferi daripada penderma yang normal dan mereka dengan penyakit lain yang berkaitan dengan hemoglobin ( $p < 0.05$ ). Tahap ekspresi adalah amat berbeza antara pesakit LLA. Oleh yang demikian, analisis *TERF2* yang seterusnya dijalankan mengikut sub kumpulan yang berbeza. Ekspresi *TERF2* yang sangat tinggi dijumpai dalam subkelompok LLA, *TEL-AML1* – yang mempunyai tindak balas lebih baik terhadap kemoterapi. Sementara itu ekspresi rendah didapati pada sub kumpulan *BCR-ABL1* yang mempunyai tindak balas kurang baik kesan buruk terhadap rawatan kemoterapi.

Penyelidikan kami menunjukkan bahawa ekspresi *TERF2* yang tinggi memberikan kesan perlindungan terhadap kromosom dan sebaliknya kesan buruk kepada sel-sel kanser.

Kesimpulannya, kumpulan *TEL-AML1* yang mempunyai ekspresi *TERF2* yang tinggi dikaitkan dengan prognosis yang baik sedangkan sebaliknya adalah benar untuk pesakit dengan penyakit positif *BCR-ABL1*. Ia melindungi telomer dan kemudian membantu kestabilan kromosom, sehingga membolehkan sel untuk mengalami kematian sel normal. Kami berhipotesis bahawa kemampuan sel kanser untuk mengekalkan kitaran sel normal dan menjalani apoptosis membolehkan agen kemoterapi yang berbeza untuk bertindak pada pelbagai tahap kematian sel pusat. Ia membolehkan rawatan lebih efektif dan meminimumkan kadar penyakit berulang. Kami menyimpulkan bahawa ekspresi tinggi *TERF2* memberi kesan rawatan yang lebih baik pada pesakit LLA. Saiz sampel yang lebih besar dan kajian pada tahap protein diperlukan untuk mengesahkan hasil kajian ini.

## **ACKNOWLEDGEMENTS**

I thank Almighty God for His blessings, whereby only with His permission, I am able to complete my thesis.

It's a pleasure to thank all the people who made this thesis possible. First and foremost, I would like to express my gratitude and greatest appreciation to my supervisor, Prof. Dr Hany Ariffin who undertook to act as my supervisor despite her clinical and academic commitments. Her wisdom and knowledge throughout this study has inspired and motivated me to the highest standards.

I would like to thank Dr Normawati Zahari from Institute of Biological Science (Genetics), Faculty of Science, who has been very helpful throughout the duration of my research project. My colleagues, Mrs Kamariah Ibrahim, Mr Leon Lim Li Wen, Ms Choong Soo Sin and Mr Chen Kok Siong for the endless support and encouragement.

I would also like to thank my parents and my sisters who have been the fundamental base to every success I have had in life. They were always there cheering me on and stood by me through the good and bad times. Lastly, I am indebted to my friends, who never fail to help and support me.

## TABLE OF CONTENTS

ABSTRACT .....	
ACKNOWLEDGEMENTS .....	iv
LIST OF FIGURES .....	vii
LIST OF TABLES .....	viii
LIST OF ABBREVIATIONS .....	ix
CHAPTER 1: INTRODUCTION .....	1
1.1 Overview of Childhood Cancer.....	1
1.2 Telomere .....	5
1.3 Telomerase .....	6
1.4 Telomere Repeat Binding Factor 2 ( <i>TERF2</i> ) .....	7
1.5 Significance in cancer .....	8
Chapter 2 – LITERATURE REVIEW .....	9
2.1 Childhood ALL .....	9
2.1.1 Background.....	9
2.1.2 Clinical Presentation.....	11
2.1.3 Pathobiology and pathophysiology .....	12
2.1.4 Prognosis.....	14
2.2 Molecular Characterization .....	15
2.2.1 Numeric chromosomal changes .....	15
2.2.2 Structural Chromosome changes.....	15
2.3 Telomerase Binding Factor <i>TERF 2</i> .....	20
2.3.1 Role and expression of <i>TERF2</i> in Cancer .....	20



CHAPTER 3: PATIENTS AND METHODS .....	21
3.1 Project Outline.....	21
3.1.1 Patient and control samples .....	21
3.1.2 Ethical approval .....	23
3.1.3 Tissue sample collection.....	25
3.1.4 Isolation of Lymphoblasts .....	25
3.1.5 RNA extraction .....	27
3.1.6 Reverse Transcription PCR (RT-PCR) for Gene Expression.....	29
3.1.7 Conventional PCR for the assurance of cDNA quality .....	31
3.1.8 Quantitative Real-Time PCR for gene expression .....	33
3.2 Validation of the Method .....	36
3.2.1 Selection of calibrator sample.....	36
3.2.2 Internal reference gene validation .....	38
3.2.3 Relative Quantitation of gene expression .....	40
CHAPTER 4 – RESULTS.....	45
4.1 Main findings .....	45
4.2 Determining Cut-Off Value of <i>TERF2</i> Expression .....	50
CHAPTER 5: DISCUSSION AND CONCLUSION .....	56
CHAPTER 6: APPENDIX .....	61
6.1: Patients information sheet.....	61
6.2: Patient information sheet for chemotherapy and cell banking.....	64
6.3: Consent form for bone marrow cell collection.....	65
6.4 Protocol MA-SPORE-ALL-2003 treatment overview .....	66
CHAPTER 7: BIBLIOGRAPHY .....	69

## LIST OF FIGURES

Figure 1.1: White blood cells

Figure 1.2: Lymphoblast

Figure 1.3: Human telomeres

Figure 1.4: T-loop and shelterin complex

Figure 2.1: Ten most frequent cancers in males

Figure 2.2: Lymphatic leukemia according to age group

Figure 2.3: Distribution of translocation-associated oncogenes in childhood ALL

Figure 3.1: Expression of *TERF2* in different type of cell lines

Figure 3.2: Serial dilution of the cDNA is carried out for both *TERF2* and  $\beta 2M$  gene.

Figure 3.3: Linear graph for serial dilution for *B2M* gene

Figure 3.4: Linear graph for serial dilution for *TERF2* gene

Figure 3.5: Amplification efficiency comparison of *TERF2* and  $\beta 2M$

Figure 4.1: Histogram of *TERF2* expression in diagnostic marrow samples in 72 patients with acute lymphoblastic leukemia.

Figure 4.2: *TERF2* gene expression of the diagnostic bone marrow in childhood acute leukemia

Figure 4.3: Box and whisker representation of relative fold of *TERF2* expression in 33 samples from different groups.

Figure 4.4: Box and whisker plot representation of relative fold *TERF2* expression in 75 diagnosis marrows in acute lymphoblastic leukemia with different cytogenetic subtypes.

Figure 4.5: Receiver operating curve analysis

Figure 4.6: The dot diagram

Figure 4.7: Kaplan-meier analysis of *TEL-AML1* and *BCR-ABL1* patients

Figure 4.8: Kaplan-Meier analysis of survival vs genotype

Figure 4.9: Kaplan-Meier analysis of relapse-free survival in 72 ALL patients

## LIST OF TABLES

Table 1.1: Cancer Incidence rates in children

Table 3.1: Patients' and control bone marrow samples taken at diagnosis.

Table 3.2: Control samples

Table 3.3: Solid tumours samples

Table 3.4: Clinical characteristics of 75 patients with ALL at diagnosis

Table 3.5: Preparation of the RT-PCR master mix.

Table 3.6: Cycling conditions for RT-PCR

Table 3.7: Preparation of conventional PCR master mix

Table 3.8: Cycling conditions for conventional PCR

Table 3.9: Reaction components for SYBR-Green Real-Time PCR

Table 3.10: SYBR-Green Real-Time cycling condition for Rotor-Gene

Table 3.11: The primer sequences for PCR reactions

Table 3.12: The name of the cell lines, immunophenotypes and karyatypes

Table 3.13:  $C_T$  values of  $\beta 2M$  gene for different patient diagnosis

Table 3.14: Mean values of both *TERF2* and  $\beta 2M$  genes for different log amount of cDNA

Table 4.4: Analysis of co variance (ANCOVA) was carried out to determine the relation between the underexpression of *TERF2* with clinical parameters.

## LIST OF ABBREVIATIONS

1. ALL – acute lymphoblastic leukemia
2. ALT- alternative lengthening of telomeres
3. AML – acute myeloid leukemia
4. ANCOVA-analysis of co variance
5. BCR-ABL- breakpoint cluster region V-abl Abelson murine leukemia viral oncogene homolog 1
6. BLM- Bloom syndrome protein
7. cDNA- complementary deoxyribonucleic acid
8. CML- chronic myeloid leukemia
9. CNS – central nervous system
10. CT value – critical threshold value
11. DMSO- dimethyl sulfoxide
12. DNA - deoxyribonucleic acid
13. DNA-PK DNA-dependent protein kinase
14. dNTP- deoxyribonucleotide
15. dsDNA-double stranded deoxyribonucleic acid
16. EDTA- ethylenediamine tetra-acetic acid
17. EFS- event-free survival
18. ERCC1- DNA excision repair protein
19. ETS – expressed tagged sequence
20. FISH- fluorescence in situ hybridization
21. HBSS- Hanks balance salt solution
22. HL60- Human promyelocytic leukemia cells
23. HOX11- TALE homeoproteinsHRC57
24. HRX- Histone-lysine N-methyltransferase
25. hTERT- Human telomerase reverse transcriptase

26. JMML – Juvenile myelomonocytic leukemia
27. LYL1- lymphoblastic leukemia derived sequence 1
28. MLL- mixed-lineage leukemia -
29. MYC – v-myc myelocytomatosis viral oncogene homolog (avian)
30. OFT- Oncogene Fusion Transcript
31. PARP- poly (ADP-ribose) polymerase 1
32. Ph- Philadelphia
33. POT1- protection of telomere 1
34. RAP - repressor activator protein 1'
35. RNA – ribonucleic acid
36. RQ-PCR – Real-time polymerase chain reaction
37. RT-PCR – reverse transcription polymerase chain reaction
38. SYBR-Green- Synergy Brands, Inc. Green
39. TAL1- T-cell acute lymphocytic leukemia 1
40. *TERF2* – Telomere Repeat Binding Factor2
41. TERT – Telomerase reverse-transcriptase
42. TIN- interacting nuclear protein
43. U.S. – United States
44. WBC – white blood cells
45. *β2M*- beta-2-microglobin

